What Upcoming Part D Changes Could Mean for Medicare Beneficiaries | AMCP Nexus 2024
Crescent Moore, Ph.D., Pharm.D., Director of Part D/Pharmacy at BluePeak Advisors, explains the impacts of the upcoming changes to Medicare Part D.
“For 2025, as part of the Part D redesign, we have three major changes to the Part D benefit,” Crescent Moore, Ph.D., Pharm.D., Director of Part D/Pharmacy, BluePeak Advisors. “The first is going to be that $2,000 out of pocket limit that the beneficiaries that will have that we've all heard so much about. The second is the closing of the coverage gap. The third is the Medicare Prescription payment plan.”
Beneficiaries who choose the payment plan will pay nothing at the time of pickup and then get a bill in the mail later. Payments will be spread out over the course of the year. Moore said beneficiaries with high drug costs at the beginning of the year would benefit most from this program.
Moore spoke today at AMCP Nexus 2024 held at the MGM Grand in Las Vegas. She co-led the session called, ‘CY 2025 Medicare Part D Redesign: A Medicare Odyssey.’
BluePeak Advisors is a consulting division of Gallagher Benefit Services, Inc., and specializes in Medicare.
Addressing the Challenges of AI is Imperative | AMCP Nexus 2024
October 22nd 2024There is a need for strict policies regarding the use of AI in the managed care space, according to Douglas S. Burgoyne, Pharm.D., MBA, FAMCP, adjunct associate professor at the University of Utah College of Pharmacy.
Read More
AI Benefits PBMs, Health Plans and Formulary Decision Making | AMCP Nexus 2024
October 21st 2024Health plans and PBMs are using AI to aggregate data, summarize information and enhance their formulary decision-making processes, according to Douglas S. Burgoyne, Pharm.D., MBA, FAMCP, adjunct associate professor at the University of Utah College of Pharmacy.
Read More
Technology can help address the complexities of specialty medications by automating processes and enabling proactive interventions to ensure patients stay on their critical therapies, according to Kristen Whelchel, Pharm.D., CSP, Research and Patient Care Improvement Pharmacist with Vanderbilt Specialty Pharmacy's Department of Health Outcomes and Research.
Read More
How Technology Benefits Specialty Pharmacy | AMCP 2024
October 18th 2024Kristen Whelchel, Pharm.D., CSP, Research and Patient Care Improvement Pharmacist with Vanderbilt Specialty Pharmacy's Department of Health Outcomes and Research, explains how technology identifies at-risk patients, coordinates medication refills and more.
Read More
Cancer’s Reign Over the Drug Development Pipeline Continues| AMCP Nexus 2024
October 18th 2024The FDA has already made more than a dozen cancer drug approval decisions this year and more expected in the next several months and in early 2025, according to Kaelyn Boss, who gave an oncology drug pipeline talk at the 2024 AMCP Nexus meeting this week.
Read More
